Advertisement
Advertisement
IMCR
Immunocore Holdings plc - ADR
34.00
USDSponsored
-0.50
-1.45%
Aug 07, 15:59 UTC -4
Closed
After-Market
33.75
-0.25
-0.74%
IMCR Earnings Reports
Positive Surprise Ratio
IMCR beat 13 of 23 last estimates.
57%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$115.95M
/-$0.01
Implied change from Q2 26 (Revenue/ EPS)
+0.02%
/-50.00%
Implied change from Q3 25 (Revenue/ EPS)
+11.82%
/--
Immunocore Holdings plc - ADR earnings per share and revenue
On Aug 06, 2026, IMCR reported earnings of -0.02 USD per share (EPS) for Q2 26, missing the estimate of 0.00 USD, resulting in a -356.41% surprise. Revenue reached 115.93 million, compared to an expected 112.43 million, with a 3.11% difference. The market reacted with a +3.63% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of -0.01 USD, with revenue projected to reach 115.95 million USD, implying an decrease of -50.00% EPS, and increase of 0.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Immunocore Holdings plc - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Immunocore Holdings plc - ADR reported EPS of -$0.02, missing estimates by -356.41%, and revenue of $115.93M, 3.11% above expectations.
How did the market react to Immunocore Holdings plc - ADR's Q2 2026 earnings?
The stock price moved up 3.63%, changed from $33.29 before the earnings release to $34.50 the day after.
When is Immunocore Holdings plc - ADR expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Immunocore Holdings plc - ADR's next earnings report?
Based on 12
analysts, Immunocore Holdings plc - ADR is expected to report EPS of -$0.01 and revenue of $115.95M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement